Swelling/pain in R axilla with enlarged tender axillary lymph node started day 3; ongoing; Swelling/pain in R axilla with enlarged tender axillary lymph node started day 3; ongoing; Swelling/pain in R axilla with enlarged tender axillary lymph node started day 3; ongoing; Swelling/pain in R axilla with enlarged tender axillary lymph node started day 3; ongoing; "Exhaustion" day 2 (day 1=day of vaccination); This is a spontaneous report from a contactable physician reported for a patient. A 53-year-old non pregnant female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, Lot Number: EL9264), via intramuscular route of administration, on 30Apr2021 (at the age of 53-year-old), in Arm Right, as dose 2, single for COVID-19 immunization. Medical history included coeliac disease from an unknown date and unknown if ongoing, gluten sensitivity from an unknown date and unknown if ongoing Known allergies: Gluten. Historical vaccine included BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, Lot Number: EW0158), via intramuscular route of administration, on 09Apr2021 (at the age of 53-year-old), in Arm Right, as dose 1, single for COVID-19 immunization. The patient's concomitant medications were not reported. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. List of any other medications the patient received within 2 weeks of vaccination reported as unknown. The patient had not diagnosed with COVID-19 prior to vaccination and patient had not been tested for COVID-19 since vaccination. On 01May2021 the patient experienced "exhaustion" day 2 (day 1=day of vaccination), on 02May2021, the patient had  swelling/pain in r axilla with enlarged tender axillary lymph node started day 3; ongoing. Therapeutic measures were not taken as a result of AE. The clinical outcome of fatigue was recovered on unspecified date in 2021 and remaining events was not recovered.  Query: The Pfizer US Drug safety unit recently received the attached report submitted by you via pfizersafetyreporting.com. Please help to confirm the date that you became aware of the adverse events in this report as this effects regulatory reporting timelines. This awareness date is the date you became aware of the occurrence of the reported events. If you are the patient in the case, your awareness date would be the date that you became aware you were experiencing the reported events. If you are not the patient in the case, your awareness date would be the date you became aware of the occurrence of the reported events. This awareness date represents the Pfizer receipt date of the report and reflects the earliest date that any Pfizer colleague learned of the adverse event. If you learned of these events from another Pfizer colleague, please provide the date that the first Pfizer colleague became aware of the events reported, as regulatory reporting due dates are calculated based on the first day that a Pfizer colleague became aware of the adverse events.  Response: Thanks for your patience - in general I do not monitor my inbox on the weekend.  No follow-up attempts are needed. No further information is expected.